Ocugen Inc OCGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Ocugen to Participate in Upcoming Scientific Conferences
Trading Information
- Previous Close Price
- $0.95
- Day Range
- $0.91–1.01
- 52-Week Range
- $0.69–2.73
- Bid/Ask
- $0.95 / $0.96
- Shares Outstanding
- 339.31M
- Market Cap
- $325.87M
- Volume/Avg
- 5M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 63.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 116
- Website
- https://www.ocugen.com
Valuation
Metric | OCGN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 63.48 |
Price/Cash Flow | — |
Price/Earnings
OCGN
Financial Strength
Metric | OCGN |
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 0.77 |
Interest Coverage | −5.53 |
Quick Ratio
OCGN
Profitability
Metric | OCGN |
|---|---|
Return on Assets (Normalized) | −68.91% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −93.95% |
Return on Assets
OCGN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|P!#d^bD | LOCK|H&l@P | $139B | |||
| Moderna Inc MRNA | LOCK|P%FgDM | LOCK|%># | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Q>CBkR | LOCK|t#K@ | $99B | |||
| argenx SE ADR ARGX | LOCK|cKK@TJ? | LOCK|bLY | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|h^^X$rQ | LOCK|^$! | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^?#>qls | LOCK|t^xr | $31B | |||
| Incyte Corp INCY | LOCK|p^<k<?% | LOCK|>^ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|rhd?%pw | LOCK|DD# | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%SH?%% | LOCK|x>$S^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|RhDS?#x | LOCK|Gq$ | $16B |
United States